KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Labcorp Holdings (LH) Deferred Taxes (2016 - 2025)

Labcorp Holdings' Deferred Taxes history spans 17 years, with the latest figure at -$6.1 million for Q2 2025.

  • For Q2 2025, Deferred Taxes rose 68.88% year-over-year to -$6.1 million; the TTM value through Jun 2025 reached $47.0 million, up 106.14%, while the annual FY2025 figure was -$97.6 million, 585.57% down from the prior year.
  • Deferred Taxes for Q2 2025 was -$6.1 million at Labcorp Holdings, roughly flat from -$6.1 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $96.3 million in Q4 2023 and bottomed at -$76.9 million in Q4 2021.
  • The 5-year median for Deferred Taxes is -$17.8 million (2021), against an average of -$6.6 million.
  • The largest annual shift saw Deferred Taxes plummeted 645.1% in 2021 before it soared 420.54% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at -$76.9 million in 2021, then skyrocketed by 124.06% to $18.5 million in 2022, then skyrocketed by 420.54% to $96.3 million in 2023, then decreased by 18.28% to $78.7 million in 2024, then plummeted by 107.75% to -$6.1 million in 2025.
  • Per Business Quant, the three most recent readings for LH's Deferred Taxes are -$6.1 million (Q2 2025), -$6.1 million (Q1 2025), and $78.7 million (Q4 2024).